FDA grants Fast Track to Armata's AP-SA02 for treating serious Staph infections, speeding potential approval.

Armata Pharmaceuticals received FDA Fast Track designation for AP-SA02, an intravenous multi-phage therapy targeting complicated Staphylococcus aureus bacteremia, including MRSA and MSSA strains. This status allows more frequent FDA interactions, rolling Biologic License Application review, and potential Accelerated Approval and Priority Review, aiming to expedite patient access. Positive Phase 1b/2a trial results support advancing to a Phase 3 superiority study planned for late 2026. The designation highlights the urgent need for new treatments against severe bacterial infections resistant to antibiotics.